We at WaveCyte know resulting low transfection efficiency and high cytotoxicity due to current traditional transfection methods are a prohibitive bottleneck to your scientific discovery. Using our proprietary platform, we can help you accelerate your scientific breakthroughs. WaveCyte is focused on the discovery, development and commercialization of better ways to transfect cells using a highly scalable, high-throughput non-viral cell transfection technology. Our innovative proprietary platform technology, Kitaka, builds upon a large body of scientific research, enabling us to approach cell engineering in novel ways. Kitaka platform utilizes an innovative proven approach to gently disrupt cell membranes facilitating intracellular entry and integration of even large biomolecules such as plasmid DNA, RNA and proteins into cells of interest. It is safe, less toxic, more efficient, and highly scalable platform compared to other commonly used methods such as cell electroporation or viral transduction. Our platform enable high transfection efficiency and viability even in hard to transfect cells such as primary T cells and stem cells. We aim to advance the pursuit of scientific knowledge by overcoming existing obstacles in cell transfection. Contact us at info@wavecyte.com to learn how we can help accelerate your breakthroughs.
Input your search keywords and press Enter.